TICKERNERD
Menu
BCTXBCTXHealthcare · Biotechnology

BCTX Stock Forecast: BriaCell Therapeutics Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$4.07

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$35.4M
Ticker Nerd rank
7 / 100
Median analyst target
—
Analysts covering
1
Ticker Nerd rank

BCTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BriaCell Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
7 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Volatility
32
Growth
28
Accruals
28
Revisions
25
Issuance
23
Value
20
Quality
17
Momentum
8

Size (85): Smaller than most of the companies we track.

Momentum (8): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCTX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 Aug 2025HC Wainwright & Co.MaintainsBuy$32 → $40
22 Apr 2025HC Wainwright & Co.ReiteratesBuy—
3 Feb 2025HC Wainwright & Co.MaintainsBuy—
12 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Dec 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2024HC Wainwright & Co.MaintainsBuy—
11 Sept 2024HC Wainwright & Co.ReiteratesBuy—
4 June 2024HC Wainwright & Co.ReiteratesBuy—
24 May 2024HC Wainwright & Co.ReiteratesBuy—
28 Dec 2023HC Wainwright & Co.ReiteratesBuy$18
3 Oct 2023HC Wainwright & Co.MaintainsBuy$25 → $20
28 June 2023HC Wainwright & Co.ReiteratesBuy$25
24 Feb 2023HC Wainwright & Co.ReiteratesBuy$25
14 Feb 2022HC Wainwright & Co.InitiatesBuy$25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

BriaCell Therapeutics Corp. (BCTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
1.2×

Cheaper than 67% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−175.3%

Higher than 8% of US stocks

Return on assets
−90.8%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BCTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BCTXBriaCell Therapeutics Corp.$35.4M
7
LITSLite Strategy, Inc.$35.3M
28
ATNMActinium Pharmaceuticals, Inc.$34.5M
69
NNVCNanoViricides, Inc.$33.8M
58
QNCXQuince Therapeutics, Inc.$33.2M
25
IGCIGC Pharma, Inc.$31.8M
6
CRVOCervoMed, Inc.$39.6M
29

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BriaCell Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCTX news & analysis

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

GlobeNewsWire · 5 Aug 2026positive

BriaCell announced that the FDA completed its review of the Investigational New Drug application for Bria-PROS+, issuing a Study May Proceed letter and clearing the way for a Phase 1/2a clinical study in prostate cancer. Bria-PROS+ is the company's next-generation personalized, off-the-shelf, cell-based immunotherapy, which had previously received a $2 million grant from the US National Cancer Institute.

Why it matters — FDA clearance of the IND allows BriaCell to move Bria-PROS+ into clinical evaluation in prostate cancer, a key milestone in advancing its oncology pipeline.

FAQ

Frequently asked questions about BCTX stock

Is BCTX stock a buy right now?

Of the 1 analysts covering BriaCell Therapeutics Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BriaCell Therapeutics Corp. 7 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCTX?

As at 22 Aug 2026, BriaCell Therapeutics Corp. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

What is the BCTX stock forecast for 2030?

No analyst covering BriaCell Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCTX are extrapolating price history, which says nothing about the business.

What does BriaCell Therapeutics Corp. do?

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in developing novel immunotherapies to transform cancer care.

What is the latest news on BCTX?

The most recent item we track (GlobeNewsWire, 5 Aug 2026): "BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer". BriaCell announced that the FDA completed its review of the Investigational New Drug application for Bria-PROS+, issuing a Study May Proceed letter and clearing the way for a Phase 1/2a clinical study in prostate cancer. Bria-PROS+ is the company's next-generation personalized, off-the-shelf, cell-based immunotherapy, which had previously received a $2 million grant from the US National Cancer Institute.

Company

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in developing novel immunotherapies to transform cancer care. The company focuses on cell-based cancer immunotherapies designed to harness and direct the immune system against tumors, with initial emphasis on metastatic breast cancer and other solid tumor indications. BriaCell's lead clinical candidate is Bria-IMT, a targeted immunotherapy currently in Phase 3 clinical trials that has received Fast Track designation from the U.S. Food and Drug Administration for metastatic breast cancer. The company also develops Bria-OTS, a personalized off-the-shelf immunotherapy platform, and is advancing next-generation platforms including Bria-OTS+, with lead candidates Bria-BRES+ for breast cancer and Bria-PROS+ for prostate cancer. Additionally, BriaCell operates BriaPro Therapeutics Corp., a subsidiary focused on binding agents, proteins, and small-molecule oncology programs designed to enhance the immune system's ability to eliminate tumors. The company operates as a research and development-focused enterprise, advancing multiple immunotherapy modalities through clinical evaluation and regulatory review to improve survival outcomes for cancer patients with limited treatment options.

CEO Dr. William V. Williams M.D. · 16 employees · Canada · https://briacell.com